EyePoint Pharmaceuticals, Inc. Common Stock
EYPT Real Time Price USDRecent trades of EYPT by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by EYPT's directors and management
Government lobbying spending instances
-
$80,000 Jan 15, 2023 Issue: Medicare/Medicaid Health Issues
-
$80,000 Oct 17, 2022 Issue: Medicare/Medicaid Health Issues
-
$80,000 Jul 16, 2022 Issue: Medicare/Medicaid Health Issues
-
$80,000 Apr 15, 2022 Issue: Medicare/Medicaid Health Issues
-
$80,000 Jan 17, 2022 Issue: Medicare/Medicaid Health Issues
-
$80,000 Oct 17, 2021 Issue: Health Issues Medicare/Medicaid
-
$80,000 Jul 17, 2021 Issue: Medicare/Medicaid Health Issues
-
$80,000 Apr 19, 2021 Issue: Health Issues Medicare/Medicaid
-
$90,000 Jan 20, 2021 Issue: Budget/Appropriations Medicare/Medicaid Health Issues
-
$90,000 Oct 19, 2020 Issue: Budget/Appropriations Medicare/Medicaid Health Issues
-
$90,000 Jul 19, 2020 Issue: Health Issues Medicare/Medicaid
-
$90,000 Apr 19, 2020 Issue: Health Issues Medicare/Medicaid
-
$10,000 Oct 21, 2019 Issue: Health Issues
-
$20,000 Jul 17, 2019 Issue: Health Issues
-
$20,000 Apr 22, 2019 Issue: Health Issues
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Compositions, formulations and methods for treating ocular diseases Nov. 26, 2024
-
Patent Title: Method of treating an ocular condition by administering a humanized monoclonal antibodies that target ve-ptp (hptp-beta) Nov. 19, 2024
-
Patent Title: Ocular injector Sep. 24, 2024
-
Patent Title: Tie-2 activators targeting the schlemm's canal Aug. 20, 2024
-
Patent Title: Methods for treating vascular leak syndrome and cancer Jul. 23, 2024
-
Patent Title: Method of treating ocular conditions by administering an antibody that activates tie2 and binds vegf Jan. 16, 2024
-
Patent Title: Methods of treating intraocular pressure with activators of tie-2 Jun. 06, 2023
-
Patent Title: Small molecule activators of tie-2 Mar. 28, 2023
-
Patent Title: Formulations of tie-2 activators and methods of use thereof Aug. 16, 2022
-
Patent Title: Bioerodible drug delivery devices Apr. 12, 2022
-
Patent Title: Tie-2 activators targeting the schlemm's canal Feb. 22, 2022
-
Patent Title: Humanized monoclonal antibodies that target ve-ptp (hptp-beta) Nov. 23, 2021
-
Patent Title: Bioerodible silicon-based devices for delivery of therapeutic agents Jun. 08, 2021
-
Patent Title: Injector apparatus Jul. 30, 2019
-
Patent Title: Ocular inserter Jun. 18, 2019
-
Patent Title: Bioerodible sustained release drug delivery systems May. 28, 2019
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of EYPT in WallStreetBets Daily Discussion
Recent insights relating to EYPT
Recent picks made for EYPT stock on CNBC
ETFs with the largest estimated holdings in EYPT
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view EYPT Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.